Gen Z and boomers are driving a leadership vacuum that's threatening productivity and morale at work
A perfect storm may soon hit leadership in corporate America, with baby boomers retiring and Gen Z unenthused about climbing the career ladder. However, experts argue that slashing development budgets and stereotyping young people as lazy is only making matters worse.
Who wants to be the boss anymore? According to the headlines, not Gen Z.
The bright young minds of tomorrow are just not striving to climb the corporate ladder as much as their older colleagues, but it's not coming from a lack of interest in management.
Instead, a generational disconnect in how leaders should wield their power is to blame. Gen Z employees are concerned about leadership's basic interpersonal skills, and nearly half of them want better communication and teamwork training, according to a recent Korn Ferry report. Major companies like Amazon are cutting middle manager roles, leaving early-career employees left without a model of leadership pathways. About 41% of employees say that their organizations have done away with middle management, according to the same Korn Ferry report.
The pool of future leaders continues to shrink, with layoff uncertainty and disengagement leading to low morale among workers just getting their feet wet in the working world. Over half of Gen Z employees don't even want to become managers, according to recruitment company Robert Walters. After seeing their bosses get burned out and laid off, it's not surprising that the youngest generation of workers doesn't want the same fate. As boomers look to hang up their badges and retire, this growing leadership vacuum threatens the modern workforce.
Katie Trowbridge, a multi-generational workplace strategist, is trying to help bridge the leadership gap. She spent twenty-three years as an educator, working with millennials and Gen Zers and identifying their core values, how they work best, and what motivates them.
'[Younger generations] want to have a purpose, and they want to see how what they're doing matters and has relevancy,' she tells Fortune. Trowbridge argues that this mindset can differ from their predecessors, many of whom were taught to 'put your head down and get to work.'Young people lead with curiosity, Trowbridge argues, and that curiosity should be fostered, not discouraged. She stresses that leaders are failing to coach young staffers because they're buying into stereotypes around Gen Z's work ethic.
'We tag them as lazy. They're not lazy. They are far from being lazy. They just are curious and they want knowledge,' she says. 'They're just asking us to teach them how to do it.'
While Gen Z may be asking, Trowbridge doesn't believe that today's leaders are answering.
Corporate investment in leadership development has been dropping substantially, with average budgets dropping 70% from January 2023 to January 2024, according to recent data from LEADx. Budgets have slipped even further, with a 15% drop from January 2024 to the same time this year.
Leaders shouldn't assume that their workers have the same priorities as they do, especially when it comes to work-life balance. Trowbridge notes that long gone are the days when a job takes precedence over all else.
'One of the things that millennials and Gen Zers are getting right is that they are not allowing work to be the thing that defines them.' It is in the best interest of current leaders to abandon much of the rigidity that has defined work culture for the past few decades, she argues.
Another solution that Trowbridge touts is thinking small. Gen Z workers are leaning more and more into the gig economy, and one way to gain back trust is to run individual departments as their own small businesses, with a more personalized approach that emphasizes individual career growth.
'[Companies are] going to have to make sure that there's that mentorship, that coaching going on, that there is that connection [and] team building really happening.'
This story was originally featured on Fortune.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
29 minutes ago
- CNET
At $185, These Samsung Galaxy Buds 3 Pro Just Matched an Amazon All-Time Low
Samsung makes just about everything these days, including some of the best wireless earbuds on the market. The Samsung Galaxy Buds 3 Pro have all the features you'd expect from premium earbuds, and this is your chance to pick a pair up with a $65 discount. Thanks to this Amazon deal, you can currently get these incredible earbuds for just $185. That's the lowest price that we've seen Amazon sell these earbuds for, although it doesn't quite match a previous Woot deal that slashed them even further. That deal was for the international version, though, and you only got a 90-day warranty. Amazon's offer gets you the US version with a full two-year warranty, so that's worth keeping in mind. We can't vouch for how long this deal will last, which means you should definitely consider ordering soon. It's a limited-time deal, so it won't last forever. Hey, did you know? CNET Deals texts are free, easy and save you money. You'll definitely regret missing out if you're too late, too. These earbuds have a redesigned fit, which is said to offer a more comfortable listening experience. They're IPX7 water resistant, so you can use them when out in the rain and whatnot, and the noise cancellation features make them a perfect companion for loud offices and noisy commutes. In terms of battery life, Samsung says you can look forward to up to 8 hours, depending on whether you're using ANC or not, while the included charging case bumps that to 18 hours. Fast-charging tech ensures you can get a battery boost when needed, too. Because of all of this, this is easily one of the best wireless earbuds deals around right now. Why this deal matters Getting great features often means spending great sums of money, which is why we're always keen to share deals like this one. If you'd eyed these wireless earbuds in the past but balked at their $250 price tag, now's your chance to pick them up for less. Just make sure you do it before Amazon calls time on this deal.
Fast Company
30 minutes ago
- Fast Company
From immigration law to business success: Navigating the challenges for foreign business in the U.S.
As a U.S. business immigration attorney and founder of Grape Law Firm PLLC, I have worked with many foreign entrepreneurs who have achieved lasting success in the United States. Establishing and scaling a company here requires time, effort, and strategic planning to navigate a complex web of immigration regulations and compliance requirements. COMMON LEGAL HURDLES IN SECURING EMPLOYEE VISAS The primary challenge faced by businesspeople is securing a legal presence in the United States. This means obtaining the appropriate visa or status for both entrepreneurs and their essential personnel. However, the process of business immigration to the U.S. is often a challenging adventure. According to the 2024 CIS Ombudsman Annual Report, from initial market entry to business expansion—and even to permanent establishment—the complexities of business immigration affect entrepreneurs at every stage of their U.S. journey. They face significant challenges in documenting the viability of their enterprises to immigration officials while managing their immigration status to meet the changing needs of the business ecosystem. NAVIGATING VISA PATHWAYS FOR BUSINESS GROWTH As business immigration attorneys, one of our primary duties is to help our clients choose the most suitable visa for their business vision and goals. The selection of the appropriate visa is the foundation on which a successful application strategy is built and is an investment in the company's long-term growth. It is imperative for entrepreneurs to understand that various options exist for starting new businesses in the United States or expanding existing operations. Each visa category has its own distinct advantages and considerations based on differing business needs. For instance, the E‑1 Treaty Trader and the E‑2 Treaty Investor visas are viable options for entrepreneurs. These visa categories cater to foreign traders and investors who are citizens of treaty countries—countries that have treaty agreements with the U.S. Traders must engage in continuous trade with the United States, and the U.S. must be their primary trading partner. Conversely, investors must make substantial investments through new or existing enterprises. Both the E‑1 and E‑2 visas can support long-term, sustainable business ventures in the United States (each is valid for up to five years and can be extended indefinitely), provided that they spur economic progress in their respective industries and investment areas. Furthermore, the L‑1 Intracompany Transferee visa is an ideal choice for international companies planning to expand to the U.S. The L‑1 visa allows foreign companies to transfer their managerial or executive employees for new office openings, thereby facilitating the establishment of operations in the United States. However, a potential downside is that the L‑1 visa requires rigorous application preparation—a thorough case file must be compiled, followed by consistently detailed documentation of organizational development and business growth metrics, especially during the first three years of operations. A CASE IN POINT One case from our L‑1 visa practice perfectly illustrates these complexities. As a seasoned professional in the scaffolding industry, our client's initial L‑1 New Office visa application succeeded through careful preparation and a comprehensive five‑year business plan. However, the real challenges emerged during the extension phase. When she sought to extend her L‑1 visa with different legal counsel, she faced a rigorous Request for Evidence (RFE) from USCIS that scrutinized every aspect of her business operations. The RFE questioned not only the structure, but also its growth trajectory and staffing decisions—common challenges that many foreign businesses face in proving the legitimacy and sustainability of their operations. The industry's unique characteristics, including its project‑based nature and specialized staffing requirements, made it particularly challenging to conform to USCIS's traditional expectations for business development. Her case is a stark reminder for prospective entrepreneurs that experienced immigration counsel can provide needed guidance throughout the ups and downs of their U.S. immigration journey. Entrepreneurs must acknowledge that deciding on the right visa type is more than an entry ticket to the United States—a visa is the key to legal rights, business investments, and financial aspirations that influence one's life in the U.S. BUILDING A FOUNDATION FOR LONG-TERM SUCCESS The U.S. business immigration ecosystem is ever-changing and demands legal acumen in business planning—integrating proactive immigration solutions from the very beginning. To achieve lasting success, entrepreneurs need expert legal guidance to navigate the complex steps of immigration and adapt to any changes or updates in the immigration system. Beyond legal counsel, success often hinges on comprehensive preparation and strategic planning. Maintaining detailed business documentation from day one proves crucial for immigration success. Successful immigrant entrepreneurs often distinguish themselves through meticulous record-keeping of business transactions, employee contracts, and market analyses that demonstrate their enterprise's viability. Early strategic planning should include developing detailed business projections, establishing clear organizational structures, and creating systems for tracking achievements and metrics. These elements strengthen visa applications and create a foundation for sustainable growth. Networking within industry associations and chambers of commerce can provide valuable insights into immigration processes and business development. Furthermore, entrepreneurs who actively participate in their industry's ecosystem often find themselves better positioned to demonstrate their legitimacy to immigration authorities. This comprehensive approach, combining thorough documentation with strategic foresight, guarantees that immigration planning aligns with business goals while maintaining strict compliance with U.S. regulations. As we look to the future, business expansion into the United States and immigration to the country will only become more interlinked. In that regard, the aforementioned success story of our entrepreneur client is an excellent example—showcasing that viewing immigration not as a hurdle but as a strategic tool is essential for success. Always remember: proper planning, combined with expert guidance, can transform potential obstacles into opportunities for growth in the American market. The key to sustainable success lies in developing a nuanced understanding of how immigration pathways can support business objectives while ensuring compliance with regulatory requirements.
Forbes
30 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
